Podcasts about zepbound

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. Some of the best conversations start with listener questions, especially the ones that come from feeling stuck, confused, or wondering, 'is this normal?'In this special Q&A episode, I'm tackling two listener questions. One is about unexpected dryness while taking a GLP-1 medication. The other is a much bigger one: what to do when weight loss slows down after an initial drop, even though you feel like you're trying.Join me as I talk about the importance of success beyond the scale, why BMI is useless without body composition data, and why movement matters more for your brain than your waistline.If you've been feeling frustrated, stalled, or unsure what to focus on next, this episode will help you think about your situation a little differently.ReferencesThe Body Intelligence Blueprint Audio Stamps00:29 – 30/30 program updates and changes for the September round.03:40 – Dry lips and skin on Zepbound: what's normal vs. what needs medical attention.05:28 – Redefining success beyond the scale and celebrating non-scale victories.07:15 – Why body composition data matters more than BMI for tracking real progress.08:07 – Exercise as a tool for emotional resilience and stress management.09:58 – Why checking labs and ruling out physiological causes should always come first.11:46 – Introducing the Body Intelligence Blueprint: personalized one-on-one coaching with genome analysis and body composition.All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Not Sure Where to Start With the Podcast? I've Got You.Get my free Podcast Roadmap—a simple guide to help you find the episodes that matter most to your journey. Whether you're on GLP-1s, navigating plateaus, or just starting out, there's something here for you.Support the show

Dr. Natalie Crawford, board-certified OB-GYN and REI, answers your fertility questions. Questions Answered: 1. A 30-year-old in a same-sex couple with anovulatory PCOS managed on metformin, high AMH, and otherwise normal labs moved from failed IUIs to IVF and had 19 mature eggs but only 4 fertilized despite good donor sperm—what could explain low fertilization rates and how should the next steps be approached? 2. 35 and trying for baby number two, and her 40-year-old husband has been on the GLP-1 medication Zepbound for four months—are there known effects of GLP-1s on male fertility, and should men discontinue them while trying to conceive? 3. A patient with PCOS and mildly elevated thyroid levels is experiencing medication interactions and was prescribed 2.5 mg of methylfolate— is this dose appropriate, and should she be taking methylfolate, folic acid, or both? 4. A patient with endometriosis underwent two egg retrievals, one with estrogen priming that triggered an endometriosis flare and resulted in very high estrogen levels and poor egg maturity—are there stimulation protocols better suited for patients with endometriosis undergoing IVF? 5. A 38-year-old planning IUI with donor sperm, normal fertility workup, AMH of 3.3, and a personal history of being a twin is deciding between natural versus medicated cycles— which approach is more successful while minimizing twin risk and preserving future fertility goals? Pre-order Dr. Crawford's debut book, The Fertility Formula, now! ⁠⁠⁠https://www.nataliecrawfordmd.com/book⁠⁠⁠ Want your questions answered on the next episode? ⁠Ask them here!⁠ ⁠https://www.nataliecrawfordmd.com/qa-submissions⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Join Mark, Kate, Henry and Gary as they discuss 4 new POEMs (Patient Oriented Evidence that Matters, studies with the potential to change practice): a summary of the evidence on tirzepatide (Zepbound) for weight loss, using the Beers list with your patients, high vs standard dose flu vaccine and the risk of hospitalization, and whether stent or endarterectomy are better than maximal medical therapy for patients with asymptomatic carotid stensosis. Here are the links:Essential Evidence Plus: www.essentialevidenceplus.comTirzepatide systematic review: https://pubmed.ncbi.nlm.nih.gov/41015578/ Tirzepatide vs dulaglutide: https://pubmed.ncbi.nlm.nih.gov/41406444/Applying the Beers list: https://pubmed.ncbi.nlm.nih.gov/40697073/ High vs standard dose flu vaccine: https://pubmed.ncbi.nlm.nih.gov/41115437/ Another high dose flu trial: https://pubmed.ncbi.nlm.nih.gov/39230284/ Asymptomatic carotid stenosis treatment: https://pubmed.ncbi.nlm.nih.gov/41269206/

I recently read something that stopped me in my tracks: being fat robbed me of my femininity.And I haven't been able to shake it.In this episode, I pose a question that came out of a Reddit thread but really speaks to a shared experience so many of us quietly lived: growing up, did femininity ever feel like it wasn't meant for you?I'm sharing my own experiences of being invisible next to friends, being talked about like I wasn't even a person, not being able to shop where other girls shopped, missing out on certain “girlhood” moments, and learning very early on which bodies were allowed to be soft, desired, and feminine and which weren't.We'll talk about how those moments shape us long after childhood, how confidence can coexist with old wounds, and what it actually looks like to take your femininity back without performing it or earning permission.If you've ever felt like girlhood passed you by, or like femininity came with conditions you didn't meet, this episode is for you. You're not alone—and you didn't imagine it.Show Notes!

Send us a textIn this episode, we open an honest, shame-free conversation about GLP-1 weight-loss medications like Ozempic, Wegovy, and Zepbound, and why choosing—or not choosing—medical support doesn't have to become a test of faith. Together, we explore the real questions many believers quietly carry: Am I taking a shortcut? Does this mean I don't trust God enough? We name the pressure, untangle medicine from morality, and remind listeners that wisdom and faith are not at odds. God is not keeping score, and health decisions don't need to be driven by fear, comparison, or guilt.We then walk through a practical four-step discernment process: asking with open hands, examining motives honestly, inviting wise counsel, and staying grounded in Scripture. Drawing from passages like Proverbs 3:5–6, James 1:5, Romans 12:2, Galatians 5:1, and Romans 8:1, we offer guidance for both those considering GLP-1s and those already using them—emphasizing ongoing renewal of the mind and closeness with Jesus so medication remains a tool, not a replacement for spiritual growth. You'll come away with reflection questions, helpful language for conversations with doctors and trusted leaders, and a renewed vision for health shaped by love, freedom, and wisdom. No matter your choice, the heart of change stays the same: Christ leads, shame has no authority, and God meets us as we listen.Class starts December 10thhttps://teamlifeisgood.com/goSupport the showLearn more about our Revelation Within Community: https://www.revelationwithin.org

Send us a textIn this episode of On The Pen: The Weekly Dose, Dave Knapp breaks down why the idea of over-the-counter GLP-1 medications isn't radical speculation, it's a pattern already in motion. Drawing on FDA signals, past regulatory precedent with Orlistat, recent pricing negotiations, softened safety language, and public comments from pharmaceutical executives, Dave lays out the case that low-dose oral GLP-1s could be the first step toward OTC access. This episode connects the dots between regulation, access, pricing, and normalization of obesity treatment, and explains why the people laughing today may be asking how they missed it tomorrow.

Send us a textShantanu Gaur, CEO of Allurion, returns to the podcast to break down their swallowable inflatable weight loss balloon, how it works, who it is for, how much it is expected to cost, and when patients can realistically expect access.We talk real world weight loss results, safety, availability in the US, and how Allurion fits into the broader obesity treatment conversation alongside GLP-1 medications and bariatric options.This is a clear, no hype discussion for patients who want more tools and better choices in obesity care.More Info:OTPLinks.com

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever wondered what's really changing the game in weight loss treatments? Well, oral Wegovy might be it. Unlike other GLP-1 medications that require weekly injections, this is the first long-term weight-loss pill in its class. For many people, taking a daily tablet just feels way more doable—it's flexible, lowers mental barriers, and makes managing weight something that can actually fit into everyday life.In this episode, my guest is Joseph “Joe” Zucchi, a physician assistant and personal trainer with over a decade of experience in obesity medicine. He leads a multidisciplinary team in Salem, New Hampshire, helping patients achieve sustainable weight loss through a mix of fitness, nutrition, and medical care. Joe has been recognized for his work—leading his center to win awards, writing for outlets like the Wall Street Journal, MedPage Today, Healthline, and Doximity, and advocating for patient access to treatments like Zepbound. His insights make it clear that oral Wegovy isn't just another pill—it's part of a thoughtfully designed, patient-centered approach to obesity care.In this episode, we break down everything you need to know, including GLP-1 medications in simple terms, the future of oral Wegovy, what counts as success on the pill, side effects to expect, the technology behind it, how to take it properly, safely transitioning between pill and injection, who benefits most (and who should avoid it), and cost, coverage, and what to expect in 2026. If you've been curious about how oral Wegovy works and whether it could be right for you, this episode walks through it all in practical, real-world terms.Connect with Mr. Zucchi:Linkedin: Joseph Zucchi, PA-CX: JPZfitness Instagram: transitionweightlossConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Dr. Tien Lee, Founder and CEO of Aardvark Therapeutics, draws a clear distinction between appetite and hunger and the implications for treating metabolic conditions and managing weight. The Aardvark lead drug candidate, an oral bitter taste receptor agonist designed to activate the gut-brain connection to turn off hunger, is showing effectiveness in treating Prader-Willi Syndrome and general obesity.  There are also signs that this drug could be effective for those using GLP-1s to avoid nausea and prevent rebound weight gain experienced after discontinuing GLP-1 drugs. Tien explains, "That difference between hunger and appetite is the central thesis for our entire company, and your brain actually regulates how much you should eat. And it's driven by both appetite and hunger. So appetites like the carrot, and hunger is like the stick. Appetite is what you feel when you really enjoy a certain food, like ice cream or cake. And the appeal and the deliciousness of that food is a reward that your brain chases. Hunger is the feeling that you get when you have fasted for a prolonged period of time, and it really bothers you, and you feel real discomfort from not eating. And then at that point, food quality matters less, and you just want to escape that negative sensation. And we believe a lot of the current drugs are good at reducing appetite, but they don't so much address hunger like what our approach is pursuing."  "In obesity, there's probably a combination of both appetite and hunger at play. And they're both important. In fact, your body has both appetite and hunger that are regulated. And when we eat food, our gut releases a number of gut hormones that help tamp down and give us satiety for both appetite and hunger. However, there are certain conditions where hunger is the predominant issue. And with the disease that is our lead indication is a condition called Prader-Willi syndrome. It's a rare genetic disorder that affects about one out of 15,000 live births. And patients with this condition have this unabated, unrelenting hunger that they feel that really starts to manifest when they're about four or seven years old. And then characteristically, patients will even feel compelled to eat garbage to the point of stomach rupture if unregulated with their food access. So it's a very debilitating condition with a lot of suffering for the patients and their families."   "There are actually quite a number of new revelations in the scientific literature, and there's a greater appreciation of gut-brain signaling. So there are actually as many neurons in your gut as there are in your spinal cord, almost as many neurons as in the cat brain. And there's a greater appreciation of a two-way communication between your brain and the gut. So the vagus nerve is the largest nerve in your body, and there's actually a two-way communication between the gut and the brain. About 80% to 90% of the signal is actually from the gut to the brain. And even the drugs that people know currently, the Ozempic and the Zepbound drugs, are working through this gut path hormone. But naturally, a lot of the signals actually come from the gut to the brain through this vagus nerve conduction." #AardvarkTherapeutics #Hunger #Appetite #PraderWilliSyndrome #PWS #Hyperphagia #RareDiseases #BiotechInnovation #ObesityTreatment #GutBrainAxis #TasteReceptors #ClinicalTrials #Therapeutics #MetabolicHealth #PharmaceuticalInnovation  aardvarktherapeutics.com Download the transcript here

Dr. Tien Lee, Founder and CEO of Aardvark Therapeutics, draws a clear distinction between appetite and hunger and the implications for treating metabolic conditions and managing weight. The Aardvark lead drug candidate, an oral bitter taste receptor agonist designed to activate the gut-brain connection to turn off hunger, is showing effectiveness in treating Prader-Willi Syndrome and general obesity.  There are also signs that this drug could be effective for those using GLP-1s to avoid nausea and prevent rebound weight gain experienced after discontinuing GLP-1 drugs. Tien explains, "That difference between hunger and appetite is the central thesis for our entire company, and your brain actually regulates how much you should eat. And it's driven by both appetite and hunger. So appetites like the carrot, and hunger is like the stick. Appetite is what you feel when you really enjoy a certain food, like ice cream or cake. And the appeal and the deliciousness of that food is a reward that your brain chases. Hunger is the feeling that you get when you have fasted for a prolonged period of time, and it really bothers you, and you feel real discomfort from not eating. And then at that point, food quality matters less, and you just want to escape that negative sensation. And we believe a lot of the current drugs are good at reducing appetite, but they don't so much address hunger like what our approach is pursuing."  "In obesity, there's probably a combination of both appetite and hunger at play. And they're both important. In fact, your body has both appetite and hunger that are regulated. And when we eat food, our gut releases a number of gut hormones that help tamp down and give us satiety for both appetite and hunger. However, there are certain conditions where hunger is the predominant issue. And with the disease that is our lead indication is a condition called Prader-Willi syndrome. It's a rare genetic disorder that affects about one out of 15,000 live births. And patients with this condition have this unabated, unrelenting hunger that they feel that really starts to manifest when they're about four or seven years old. And then characteristically, patients will even feel compelled to eat garbage to the point of stomach rupture if unregulated with their food access. So it's a very debilitating condition with a lot of suffering for the patients and their families."   "There are actually quite a number of new revelations in the scientific literature, and there's a greater appreciation of gut-brain signaling. So there are actually as many neurons in your gut as there are in your spinal cord, almost as many neurons as in the cat brain. And there's a greater appreciation of a two-way communication between your brain and the gut. So the vagus nerve is the largest nerve in your body, and there's actually a two-way communication between the gut and the brain. About 80% to 90% of the signal is actually from the gut to the brain. And even the drugs that people know currently, the Ozempic and the Zepbound drugs, are working through this gut path hormone. But naturally, a lot of the signals actually come from the gut to the brain through this vagus nerve conduction." #AardvarkTherapeutics #Hunger #Appetite #PraderWilliSyndrome #PWS #Hyperphagia #RareDiseases #BiotechInnovation #ObesityTreatment #GutBrainAxis #TasteReceptors #ClinicalTrials #Therapeutics #MetabolicHealth #PharmaceuticalInnovation  aardvarktherapeutics.com Listen to the podcast here

This episode opens the year with one of the most consequential—and complicated—weeks in GLP-1 obesity medicine. We break down three stories that, taken together, reveal why patients are increasingly reading past headlines and demanding accountability from the industry. First, we examine early-phase trial data from Arrowhead Pharmaceuticals, after headlines claimed its experimental INHBE-targeting therapy “nearly doubled” the weight loss of Zepbound. We walk through what the data actually showed, why the comparison was misleading, how trial design and dosing matter, and why Phase 1 results should never be treated as superiority claims. Next, we turn to a major access milestone: the official launch of oral Wegovy, the first FDA-approved GLP-1 pill for obesity from Novo Nordisk. We discuss how this pill differs from compounded oral semaglutide, why its pricing strategy is so disruptive, and what this launch means for people who have avoided injectable medications. We also explore how direct-to-consumer access, telehealth partnerships, and retail pharmacy distribution signal a broader shift in how obesity care is being delivered. Finally, we address the most ironic—and uncomfortable—story of the week: manufacturing quality concerns involving branded Wegovy pens, reported to include biological particulate matter, at the same time Novo Nordisk continues a years-long public and legal campaign against compounded GLP-1 medications on safety grounds. We discuss FDA inspection history, the acquisition of Catalent, and why credibility depends on consistency—especially when millions of patients are paying close attention. This episode isn't anti-pharma or pharma-friendly. It's patient-first. And it asks a simple question: Who do we trust when science, marketing, access, and manufacturing all collide at once? Episode Timestamps 00:00 — Why this first episode of 2026 matters 02:10 — Hair found in Wegovy pens and why patients notice hypocrisy 06:15 — Arrowhead trial headlines vs. what the data actually shows 11:40 — Why tirzepatide dosing and trial design matter 17:30 — What INHBE targeting may actually be good for (and what it's not) 21:45 — Sponsor: SHED and access pathways for obesity care 25:10 — Oral Wegovy officially launches: what's different this time 30:20 — How the Wegovy pill works and why bioavailability matters 35:40 — Pricing, telehealth, Costco, and direct-to-consumer access 41:50 — Why pills lower barriers for millions of patients 46:10 — Manufacturing quality, Catalent, and FDA citations 52:30 — Why safety arguments against compounding are being scrutinized 58:40 — Zooming out: access, accountability, and patient trust 1:02:00 — Final thoughts and what to watch next Topics Covered GLP-1 trial hype vs. real-world context Phase 1 data limitations and headline inflation Tirzepatide dosing and misleading comparisons Oral Wegovy vs. compounded oral semaglutide GLP-1 pill pricing and insurance implications Direct-to-consumer pharma and telehealth disruption Manufacturing quality and FDA oversight Compounding pharmacies and healthcare system resilience Patient trust, transparency, and credibility in obesity medicine Useful Links & Resources On The Pen Links & Advocacy: https://otplinks.com Sponsor – SHED (use code OTP25): https://tryshed.com FDA Drug Safety & Recalls: https://www.fda.gov/drugs Follow On The Pen: YouTube: https://youtube.com/@onthepen Substack: https://onthepen.substack.com Support the Show If this episode helped you better understand what's really happening in obesity medicine: Leave a 5-star rating and review Hit Subscribe so you don't miss future episodes Join us live Mondays, Wednesdays, and Fridays at 12pm Eastern on YouTube Patients deserve clarity. That's what we're here for. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Gianna Beasley welcomes listeners to 2026 and discusses the importance of setting health goals for the new year. She outlines a roadmap for success on a GLP-1 journey, emphasizing the need for reflection, refocusing, consistency, and celebrating progress. The conversation is structured around four phases that guide listeners through their health journey, encouraging self-awareness and sustainable habits.

Feeling stuck? If your GLP-1 weight loss has slowed down or stopped, you're not alone and it does not mean the medication stopped working. In this episode, Gianna walks you step-by-step through her checklist for stalls, which she uses to help GLP-1 clients restart progress without panic, restriction, or jumping doses.Listen to learn how to fuel properly, protect your metabolism, check your consistency, and adjust habits so your results return- calmly and confidently. ✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

This week, The Daily is revisiting some of our favorite episodes of the year and checking in on what has happened in the time since.In the past few years, GLP-1 weight-loss drugs like Ozempic and Zepbound have been radically reshaping the people's lives, changing appetites and health.But the drugs also have the power to affect other parts of consumers' lives, including their romantic relationships.Lisa Miller, who writes about health for The New York Times, tells the story of how these drugs upended one couple's marriage.Guest: Lisa Miller, a domestic correspondent for the Well section who writes about personal and cultural approaches to physical and mental health.Background reading: Listen to the original version of the episode here.Weight-loss drugs have lesser-known side effects on relationships.Photo: Katherine Wolkoff for The New York TimesFor more information on today's episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

Mike Mitchell, Zach Cherry, and Jon Gabrus join the pod for a very special Christmas edition to discuss the indignities of being expected to dress as Santa when you're fat, the sick freaks who would enjoy seeing this crew dressed up as Santas, being pound-for-pound the heaviest podcast episode in history, CPAP experiences, buying holy water off Amazon, the sad reason Zepbound is saving society from senseless tragedies, asserting yourself against movie nerds in theaters, and much more. Mike, Zach, Jon and Stav help callers including a guy whose girlfriend's friends hate him after falsely accusing him of cheating, and a woman whose good lifelong friend only hangs out and parties with her boyfriend's mom.Follow Mike Mitchell:https://x.com/bdayboysmitchhttps://www.instagram.com/mynamesmitchFollow Zach Cherry:https://www.zachcherry.com/Follow Jon Gabrus :https://gabrus.com/https://twitter.com/gabrushttps://www.instagram.com/gabrus/https://letterboxd.com/gabrus/Thank you to our sponsors!Twisted Tea - https://www.twistedtea.com/locations☎️ Want to be a part of the show? Call 904-800-STAV and leave a voicemail to get advice!

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever wonder why postpartum weight loss can feel so unpredictable—and what's actually considered normal? It's a question so many new moms have. In this episode, we're breaking down what really happens to weight, metabolism, and overall health after pregnancy, without the pressure or unrealistic expectations.I'm joined by Dani, a family nurse practitioner and one of our obesity experts, who's also training to become a certified lactation counselor. Dani is deeply passionate about supporting postpartum women—especially those who are breastfeeding—a group that's often overlooked when it comes to guidance around weight, nutrition, and recovery.Together, we cover the realities of postpartum weight changes and dive into the topics that matter most, including closing the postpartum support gap, understanding normal weight patterns after pregnancy, the hormonal side of appetite and metabolism, breastfeeding and weight, and how to care for yourself after a baby. We also talk through practical ways to eat well during this season, when to consider weight management medications, what the emerging data says about GLP-1 medications during breastfeeding, and recovery and weight support for moms who aren't breastfeeding.We also explore how hormonal shifts influence hunger and metabolism, safe and realistic approaches to weight support, and practical strategies that help new moms feel supported—not rushed—during this intense and transformative period.Follow the full episode for a deeper, more honest look at postpartum wellness and the support moms truly deserve.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

GLP-1 drugs have become one of the most important developments in the pharmaceutical industry. With products like Ozempic, Wegovy, and Mounjaro in high demand, competition between drug makers is growing quickly. In this episode of Down to Business English, Skip Montreux and Dez Morgan get Down to Business with GLP-1 inhibitors — the drugs behind today's weight-loss boom. They explain who the main players are, including Novo Nordisk and Eli Lilly, and compare their leading products. Their discussion also looks at a major recent development: Pfizer's acquisition of biopharma startup Metsera, and why this deal could significantly change the market. Skip and Dez's conversation gives listeners a clear and practical introduction to competition and strategy in the pharmaceutical industry — while helping you improve your Business English. In this episode, you will learn: What GLP-1 drugs are and what they are used for. The main differences between Ozempic, Wegovy, Mounjaro, and Zepbound. Why Eli Lilly is gaining market share, especially in North America. How Pfizer's acquisition could affect future weight-loss treatments. Do you like what you hear? Become a D2B Member today for to access to our -- NEW!!!-- interactive audio scripts, PDF Audio Script Library, Bonus Vocabulary episodes, and D2B Member-only episodes. Visit d2benglish.com/membership for more information. Follow Down to Business English on Apple podcasts, rate the show, and leave a comment. Contact Skip, Dez, and Samantha at downtobusinessenglish@gmail.com Follow Skip & Dez Skip Montreux on Linkedin Skip Montreux on Instagram Skip Montreux on Twitter Skip Montreux on Facebook Dez Morgan on Twitter RSS Feed

Broadcast from KSQD, Santa Cruz on 12-18-2025: Dr. Dawn opens by examining how market competition is actually working in the weight loss drug sector. Novo Nordisk's Ozempic and Wegovy compete against Eli Lilly's Monjaro and ZepBound, with prices dropping nearly 50% as companies launch direct-to-consumer websites. The main barriers remain needles and refrigeration, driving development of oral versions. Novo's Wegovy pill awaits FDA approval for early 2026 launch at $150 monthly. Next-generation drugs show remarkable results: Eli's retatrutide causes 24% weight loss in 48 weeks, while Novo's Cagrisema combines semaglutide with amylin to reduce muscle loss. Pfizer paid $10 billion for Metsera's once-monthly drug despite significant side effects. A quick fiber tip suggests adding plain psyllium to morning coffee for cardiovascular and microbiome benefits. Start with half a teaspoon and work up to two teaspoons (10 grams) over several weeks to avoid gas. The prebiotic fiber improves glucose tolerance and may reduce cancer risk. UC San Diego scientists discovered why cancers mutate so rapidly despite being eukaryotic cells with protected chromosomes. The answer is chromothripsis, a catastrophic event where the enzyme N4BP2 literally explodes chromosomes into fragments. These reassemble incorrectly, generating dozens to hundreds of mutations simultaneously and creating circular DNA fragments carrying cancer-promoting genes. One in four cancers show evidence of this mechanism, with all osteosarcomas and many brain cancers displaying it. This explains why the most aggressive cancers resist treatment. Research from 2013 shows any glucocorticoid use significantly increases venous thromboembolism risk, with threefold increases during the first month of use. The risk applies to new and recurrent clots, affecting both oral and inhaled steroids, though IV poses highest risk and topical the lowest. Joint injections fall somewhere between inhaled and oral. Anyone with prior blood clots should avoid steroids except for life-threatening situations like severe asthma attacks requiring ventilation. A meta-analysis of 20 randomized controlled trials shows creatine supplementation helps older adults (48-84) maintain muscle mass when combined with weight training two to three times weekly. The supplement provides no benefit without exercise. Recommended dosing starts at 2 grams and works up to 5 grams daily. Vegans benefit most since they consume little meat or fish. Important caveat: creatine throws off standard kidney function tests (creatinine), so users should request cystatin C testing instead for accurate renal health assessment. A new JAMA study suggesting risk-based mammogram screening is fatally flawed. First, researchers offered chemopreventative drugs like tamoxifen only to the high-risk group, contaminating the study design. Second, the demographics skewed heavily toward white college-educated women, missing the reality that Black women face twice the risk of aggressive breast cancer with 40% higher mortality. Third, wild-type humans failed to follow instructions—low-risk women continued getting annual mammograms anyway while high-risk women skipped recommended extra screenings. The conclusion of "non-inferior" outcomes is meaningless given poor adherence. Stick with annual mammograms, and consider alternating with MRIs for high-risk women. The EAT-Lancet report condemns red meat based purely on observational data showing correlations with heart disease, cancer, and mortality. But people who eat lots of red meat differ dramatically from low consumers: they weigh more, smoke more, exercise less, and eat less fiber. Studies can't control for sleep quality, depression, or screen time. Notably, heavy meat eaters also die more in accidents, suggesting a risk-taking lifestyle phenotype. The inflammatory marker TMAO is higher in meat eaters, but starch is also pro-inflammatory. Eating red meat instead of instant ramen might improve health. A balanced diet with limited amounts beats epidemiology-based blanket statements. Dr. Dawn grades Dr. Oz's performance as CMS administrator. Starting at minus one for zero relevant experience, he earns plus two for promoting diet, exercise, and gut health on his show. He studied intensively after nomination, calling all four previous CMS directors repeatedly and surrounding himself with experienced staff (plus one). He finalized Medicare rules favoring prevention over surgery and earned bipartisan praise as "a real scientist, not radical" (plus one). He divested healthcare holdings but kept some blind trust interests (minus 0.5). He's developing a CMS app and partnering with Google on a digital health ecosystem (plus one), but supports ending ACA subsidies that will raise premiums for millions (minus one). He correctly promoted COVID vaccines and contradicted Trump's Tylenol-autism claims (plus one). Final score: 3.5 out of 5 possible points, the only positive score for any Trump health administrator.

What happens when a medication designed to help you lose weight also changes what brings you pleasure?In this solo episode, I'm doing a deep dive into what nobody's discussing about GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) and what they do to your sex life.These medications have been absolutely transformational for metabolic disease, obesity, and cardiovascular health. But they don't just work on your gut and pancreas they work centrally in your brain, in your reward pathways, in your pleasure centers.I'm sharing stories from my practice: the glamorous patient who suddenly didn't want to shop anymore. The wine connoisseur who lost interest in drinking. The foodies who can't stand restaurants. And yes, the patients whose sexual desire completely disappeared because their brain stopped experiencing reward the same way.Highlights:Why GLP-1 medications are actually anti-inflammatory powerhouses (and what that means for PCOS, endometriosis, even PGAD).How these drugs modulate dopamine and serotonin the same pathways that control sexual desire.Why improving body image doesn't always improve sexual function (the biopsychosocial model).The emerging science on GLP-1s reducing alcohol cravings, substance use, and compulsive behaviors.What SHBG changes mean for your free testosterone and libido.Why your brain doesn't compartmentalize pleasure food, shopping, alcohol, and sex all use the same reward circuits.The informed consent conversation every doctor should be having (but isn't).If you're on a GLP-1 medication or considering starting one, ask your doctor about how it might affect what brings you pleasure including sex. With great power comes great responsibility, and sexual health is health. Period.Get in Touch with Me:WebsiteInstagramYoutubeSubstackMentioned in this episode:GSM CollectiveThe GSM Collective - Chicago Boutique concierge gynecology practice Led by Dr. Sameena Rahman, specialist in sexual medicine & menopause Unrushed appointments in a beautiful, private setting Personalized care for women's health, hormones, and pelvic floor issues Multiple membership options available Ready for personalized women's healthcare? Visit our Chicago office today. GSM Collective

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements, revealing a landscape rich with scientific innovation and strategic maneuvers poised to impact patient care and the drug development pipeline.Let's start with Johnson & Johnson's recent FDA approval for a subcutaneous version of Rybrevant, their lung cancer medication. This new formulation offers a more convenient administration method compared to AstraZeneca's Tagrisso, intensifying competition in the non-small cell lung cancer market. The shift towards more patient-friendly delivery systems underscores the industry's commitment to enhancing treatment adherence and convenience. In contrast, Insmed faced a setback with its phase 2 trial for Brinsupri in treating chronic rhinosinusitis without nasal polyps. The discontinuation of this program highlights the unpredictable nature of clinical trials and emphasizes the need for rigorous scientific validation before advancing therapeutic candidates.Meanwhile, Lilly has shown promising results with its oral obesity pill, marking significant progress in weight management therapies. Patients transitioning from injectable GLP-1 therapies to Lilly's oral drug candidate maintained substantial weight loss, positioning Lilly favorably against Novo Nordisk's Wegovy. The potential for oral formulations to revolutionize treatment paradigms in chronic conditions cannot be understated. Lilly's progress in obesity treatment with its oral medication orforglipron further cements its competitive edge. Participants in their Phase III clinical trial maintained weight loss after switching from Wegovy or Zepbound to orforglipron, suggesting an efficacious oral alternative to injectable treatments and potentially enhancing patient adherence.On the regulatory front, the Biosecure Act's progression within a major defense spending bill could impose new challenges for life sciences companies with Chinese affiliations. This legislative shift reflects geopolitical tensions impacting global pharmaceutical collaborations and underscores the importance of regulatory compliance in international partnerships. Similarly, Intercept Pharmaceuticals' restructuring following the withdrawal of Ocaliva from the U.S. market is indicative of strategic pivots in response to regulatory hurdles and evolving market dynamics.In dermatology, Takeda's successful phase 3 trials for Zasocitinib highlight the competitive nature of drug development as multiple players vie for market share within therapeutic areas. Their anticipated 2026 FDA filing underscores the prolonged timelines involved in bringing novel therapies to market despite successful clinical outcomes.Public-private collaborations continue to play a crucial role in vaccine development, as evidenced by Moderna's pandemic influenza vaccine advancement into phase 3 trials with support from the Coalition for Epidemic Preparedness Innovations (CEPI). This $54 million investment illustrates ongoing efforts to bolster pandemic preparedness through innovative mRNA technologies. Meanwhile, Moderna's $54 million funding from CEPI to advance its bird flu vaccine highlights resilience amidst fluctuating governmental support. This endeavor leverages Moderna's mRNA technology platform, emphasizing mRNA's versatility across various infectious diseases.Shifting our focus slightly, medical groups have expressed opposition to changes in hepatitis B vaccination recommendations by the CDC for newborns. Such policy debates have significant implications for public health strategies and highlight ongoing discussions within medical communities regarding optimal vaccination protocols.GSK's strategic collaboration with Camp4 Therapeutics marks another key industry development. With an investment exceeding $400 million, GSK aims to Support the show

SpaceX IPO coming – huge increase in valuation over past 3 months Happy Hanukah – Eight Crazy Nights Now Kevin AND Kevin PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Last Chance for CTP Cup 2025 participants - Happy Hanukah - Eight Crazy Nights - Sad News - Rob Reiner - Fed decision is out.... - Overdue eco reports coming this week Markets - Oracle still problematic - SpaceX IPO coming - huge increase in valuation over past 3 months - Another Bankruptcy - cleaning up is not good business - Oh my - Now Kevin AND Kevin - Weight loss game continues - One thing saved for last - a doozie... Tesla -  - All time High - Prospect of Robotaxi - Even though sales hitting multi-year lows Wall Street Never Sleeps? - Nasdaq files to extend trading to 23 hours on weekdays - Banks concerned about investor protections, costs, liquidity, volatility risks of nonstop trading - Proponents argue round-the-clock trading benefits global investors - That may create some additional volatility potential SpaceX - SpaceX aims for a potential $1.5 trillion market cap with an Initial Public Offering in 2026, which could become the largest IPO in history - July 2025 tender valuation was $400B - Dec 14th (4 months later) $800B - Starlink is the primary money winner of this deal - Tesla shares climbing even with nothing behind it - seemingly in sympathy for this IPO ---- TESLA does not have ownership of SpaceX - OH - this could be the reason....U.S. deliveries dropped significantly in November—the lowest since early 2022—but this weakness has been overshadowed by the enthusiasm for autonomy. Rob Reiner - A son of legendary Hollywood director Rob Reiner and his wife, producer Michele Singer Reiner, Nick Reiner, is being held on suspicion of murder following their deaths, according to Los Angeles Police Department Chief Jim McDonnell. He's being held on $4 million bail. - Citing law enforcement sources and family friends, ABC News reported on Monday that Nick Reiner had recently returned to live at his parents' South Chadbourne Avenue home. The move was described as a temporary arrangement intended to help him stabilize. - Not going to discuss the Truth Social post about this tragedy HEADLINE ALERT - "Copper could hit ‘stratospheric new highs' as hoarding of the metal in U.S. continues" - Copper has gone from 5.77 to 5.30 (July to today) - 6 Tops at this price since 2011 - Not seeing this as per the headline - seems like a Hunt Brothers special from the 1980s - CORNERING THE MARKET ---1980 - Silver went from $11 to $50 then crashed, bankrupting the Hunt Bros - after COMEX changed rules forcing them to cover positions Bankruptcy - After 35 years, the maker of the Roomba robot vacuum filed for bankruptcy protection late Sunday night. Following warnings issued earlier this year that it was fast running out of options, iRobot says it is entering Chapter 11 protection and will be acquired by its contract manufacturer, China-based Picea Robotics. - The company says it will continue to operate “with no anticipated disruption to its app functionality, customer programs, global partners, supply chain relationships, or ongoing product support.” - Remember that Amazon  - The Amazon buyout of iRobot, maker of Roomba, was announced in 2022 for $1.7 billion but ultimately failed in January 2024 due to significant regulatory pushback, primarily from the EU, over anti-competitive concerns. -- Amazon walked away with a $94 million termination fee Fed Pick - President Donald Trump said Friday that Kevin Warsh has moved to the top of his list as the next Federal Reserve chair, though Kevin Hassett also remains in contention, according to the Wall Street Journal. - Interesting that this comes days after Hassett said that we would not let outside suggestions influence his voting - ---In addition to putting heavier weight on Warsh getting the job, Trump repeated an assertion he has made in the past that the Fed chair ought to consult the president about interest rate decisions. - Also of interest, prediction markets had Hassett at 95% probability - now it moved to 50% - big payday for people in the know. Housing Prices - Average home price is DOWN on  year-over-year basis - First time on national level since 2024 - Active listings in November were nearly 13% higher than November 2024, but new listings were just 1.7% higher --- Houses are on market longer - - Prices in Austin, Texas, are down 10% from last year; in Denver, they're down 5%, according to Parcl Labs. Tampa, Florida, and Houston both saw prices fall 4%, and Atlanta and Phoenix saw price decreases of 3%. More Hosing Related -  Zillow shares plunged more than 9% on Monday on worries that the online real estate platform could have a big new competitor: Google Search. - Google appears to be running tests on putting real estate sale listings into its search results. Overdue Eco  - Black Hole - The U.S. Bureau of Labor Statistics on Tuesday releases its long-awaited combined employment reports for October and November, but a number of key details will be missing after the government shutdown prevented data collection, including October's unemployment rate, resulting in the first-ever gap in that critical data series since inception in 1948. - NICE JOB GANG! - Some of the data will be estimated. - It said it would not publish the headline CPI number or the so-called core CPI, which strips out the volatile food and energy components, for October. "BLS cannot provide specific guidance to data users for navigating the missing October observations," the agency said. Some Updates - Some info coming in are estimates - some delayed - Unemployment at 4.6% - Latest report shows +64,000 added - ISM Manufacturing and Non-manufacturing - both slowed over the last month The Fed - Meanwhile the Fed cuts rates.... - A Federal Reserve split over where its priorities should lie cut its key interest rate Wednesday in a 9-3 vote, but signaled a tougher road ahead for further reductions. - The FOMC's “dot plot” indicated just one more reduction in 2026 and another in 2027, amid considerable disagreement from members about where rates should head. - In addition to the rate decision, the Fed also announced it will resume buying Treasury securities. The central bank will start by buying $40 billion in Treasury bills, beginning Friday. - Markets were all over the place on this as it was a little confusing at first - then it seemed that everyone loved (for one day) - Why is the Fed moving up Treasury purchases to "immediately" from a few months from now? - AND - dissension ! A larger group  that usual of regional Fed bank presidents signaled they opposed the cut, and six policymakers said the benchmark federal funds rate should end 2025 in a range of 3.75% to 4%, suggesting they opposed the move. - Long bonds have not moved at all on this news. Costco Earnings - Costco beat Wall Street's fiscal first-quarter sales and revenue expectations. - Sales rose 8.2% and digital sales jumped 20.5% compared with the year-ago quarter. - Costco surpassed Wall Street's quarterly expectations and posted year-over-year sales growth of 8.2% as the retailer attracted more digital sales and opened new locations. - Earnings per share: $4.50 vs. $4.27 expected - Revenue: $67.31 billion vs. $67.14 billion expected - Costco does not provide year ahead guidance - Shares down from a recent high of $855 Costco Fun Facts - About 4.5 million pies were sold in the three days before Thanksgiving, which is equivalent to roughly 7,000 pies per warehouse. -  These were bakery pies (e.g., pumpkin, apple), - Costco had more than $250 million in non-food online orders on Black Friday, a record for Costco's U.S. e-commerce business. - Approximately 358,000 whole pizzas were served at Costco's U.S. food courts, a 31% jump from last year. (500 pizza's per store) Fat No More - Retatrutide - Eli Lilly said its next-generation obesity drug delivered what appears to be the highest weight loss seen so far in a late-stage trial and reduced knee arthritis pain, clearing the first of several upcoming studies on the weekly injection. - In a 48-week Phase 2 study, participants on the highest dose lost an average of 24% of their body weight. - Recent Phase 3 results showed patients on the highest dose lost an average of 28.7% of their body weight after 68 weeks. - The trials also showed improvements in related health conditions, including knee osteoarthritis pain, blood pressure, and liver fat - This triple action is what makes retatrutide potentially more effective for weight loss than existing medications like Zepbound (tirzepatide), which targets two receptors, or Wegovy (semaglutide), which targets only one. Paypal - PayPal Holdings Inc. applied to become a bank in the US, looking to take advantage of the Trump administration's openness to financial-technology companies entering the banking system. - The payments-focused firm submitted applications to the Federal Deposit Insurance Corp. and the Utah Department of Financial Institutions to form a Utah-chartered industrial loan company, PayPal said in a statement Monday. - If approved, PayPal Bank would help the firm bolster its small-business lending capabilities, according to the statement, which said the company has provided access to more than $30 billion in loans and capital since 2013. Ford - Management Confused - Instead of planning to make enough electric vehicles to account for 40 percent of global sales by 2030—as it pledged just four years ago—Ford says it will focus on a broader range of hybrids, extended-range electrics, and battery-electric models, which executives now say will account for 50 percent of sales by the end of the decade. - The automaker will make hybrid versions of almost every vehicle in its lineup, the company says. - All in on EVS cost them -  Ford expects to record about $19.5 billion in special items, mostly during the fourth quarter. ---- The charges are related to a restructuring of its business priorities and a pullback in its all-electric vehicle investments. Australia - Australia has implemented a groundbreaking ban preventing children under 16 from accessing major social media platforms like TikTok, Instagram, and Facebook, effective December 2025, to protect them from harm, with significant fines for companies failing to enforce it, though messaging apps and gaming platforms are currently exempt. - Reddit is suing - Facebook, Instagram, Snapchat, Threads, TikTok, X (Twitter), YouTube, Reddit, Kick, and Twitch are all banned for kids under 16. - Thoughts on this? Saved For Last - Of all the eye-popping numbers that Oracle Corp. published last week on the costs of its artificial-intelligence data center buildout, the most striking didn't appear until the day after its earnings press release and analyst call. - The more comprehensive 10-Q earnings report that appeared on Thursday detailed $248 billion of lease-payment commitments, “substantially all” related to data centers and cloud capacity arrangements, the business-software firm said. These are due to commence between now and its 2028 financial year but they're not yet included on its balance sheet. - That's almost $150 billion more than was disclosed in the footnotes of September's earnings update. Love the Show? Then how about a Donation? The Winner for iShares Bitcoin Trust ETF (IBIT) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Participants: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

GLP-1 drugs like Ozempic, Wegovy, and Zepbound are changing medicine — but at what cost? In this episode of The Exam Room Podcast, host Chuck Carroll sits down with Ben Urich, PharmD, PhD, to break down the real-world data behind the GLP-1 explosion. You'll learn: - How many people are actually using GLP-1 drugs - Why most users stop — and why that's starting to change - The true cost of GLP-1 medications to employers and health plans - Common and serious side effects to be aware of - Why GLP-1s are now being studied for Alzheimer's disease and addiction - What the future holds as more than 30 new drugs enter the pipeline This is a must-watch conversation for anyone considering GLP-1 medications, currently using Ozempic or Wegovy, or wondering where modern weight-loss medicine is headed next.

Listen in as Jay H. Shubrook, DO, FACOFP, FAAFP, and Chrisopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMA, discuss the latest advances in caring for patients with overweight or obesity in the primary care setting, including:The Lancet Commission's new obesity definitions and diagnostic criteriaKey data on incretin-based antiobesity medications like semaglutide and tirzepatideBest practices for patient discussionsStrategies for incorporating new evidence in your primary care practicePresentersJay H. Shubrook, DO, FACOFP, FAAFPProfessor and DiabetologistDepartment of Clinical Sciences and Community HealthTouro University California College of Osteopathic MedicineVallejo, CaliforniaChristopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMABariatric Services Medical Director, Ascension WisconsinObesity Medicine Director, Ascension Columbia St Mary's Bariatric CenterTrustee, Obesity Medicine AssociationAdjunct Assistant Professor of PediatricsMedical College of WisconsinMilwaukee, WisconsinLink to full program:https://bit.ly/4rG7QQp Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Doctor Mau Informa ®️#drmauinforma 

2025: The Year America Got Thinner — But Not Healthier | Media Power Grabs & Cancer Truths 2025 is being called “the year America shed” — with more people losing weight than ever thanks to fad diets, Ozempic, Wegovy, Zepbound, and every quick-fix trend imaginable. But here's the shocking truth: Americans may be getting thinner, but not healthier. Why? Today we break down the real reasons behind the wellness illusion. Then, a massive story almost no one is paying attention to: the brewing Warner Bros. takeover battle. Donald Trump, backed by Saudi money and his son-in-law Jared Kushner, is pushing for a hostile takeover to compete with (and control) Netflix. What's the motive? What does it mean for media, entertainment, and democracy? We dig into the power dynamics behind the scenes. Plus — new, surprising research on cancer detection asks a provocative question: Should all cancers be found? The answer isn't what you think. The Karel Cast is funded by your support at patreon.com/reallykarel. Watch, like, comment, and subscribe at youtube.com/reallykarel. Listen on all major platforms: Apple Music, Spotify, iHeartMedia, Spreaker, and more. Catch the show Monday through Thursday at 10:30 AM PST, with daily clips on TikTok and Instagram. Karel is a history-making broadcaster based in Las Vegas with his service girl, Ember — bringing bold commentary, big stories, and unfiltered truth. #TheKarelCast, #2025Trends, #OzempicCulture, #WeightLossTruth, #Wegovy, #Zepbound, #AmericanHealthCrisis, #MediaTakeover, #WarnerBrosDeal, #TrumpNews, #JaredKushner, #SaudiMoney, #NetflixWar, #CancerResearch, #HealthMyths, #PoliticalCommentary, #NewsAnalysis2025, #LasVegasCreator, #LGBTQCommentator, #PodcastLife https://youtube.com/live/NPftX-i5_EU

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions about BMI cutoffs, weight cycling, metabolic adaptation, trauma, GLP-1 differences, and why some people gain weight on ultra-low calories. Dr. Cooper explains what's really happening inside the metabolic system and why individualized treatment—not dieting—creates sustainable change.Key Questions AnsweredIf my BMI doesn't “qualify” for GLP-1s, is Naltrexone + Bupropion helpful—and what labs matter first?Does being overweight always indicate metabolic dysfunction, and why are U.S. rates so high?If diets damage metabolism, what do you do when you're already 80 pounds overweight?How long does it take for leptin and ghrelin to stabilize with mechanical eating?How can someone gain weight on 1,200 calories/day?After sleeve gastrectomy, how do you eat enough while on a GLP-1?Is set point theory real—and how does the melanocortin pathway influence it?If obesity runs in my family, will I need meds like Zepbound for life?How do trauma and stress alter long-term metabolic health?Can GLP-1s offset weight gain from steroids, mood meds, or hormones?Why might Ozempic work well while Mounjaro causes weight gain?Key Takeaways1. BMI rules don't reflect metabolic truth.A mid-20s BMI can still mask significant dysfunction, especially with weight cycling.2. Weight cycling is metabolically stressful.Repeated losses/regains increase visceral fat, insulin abnormalities, and cardiovascular risk.3. Obesity is a multi-hormonal disease.Most people need pharmacology plus sleep, fueling, and movement—not restrictive dieting.4. Metabolic adaptation is powerful.Under-fueling lowers thyroid output, suppresses fat-burning, and slows metabolism dramatically.5. After bariatric surgery or on GLP-1s, frequency matters.Frequent, nutrient-dense snacks protect muscle, metabolism, and energy.6. Set point changes with better signaling.GLP-1s and related therapies help the brain accurately detect weight and lower the defended level.7. Genetics often mean lifelong support.Family patterns of obesity usually indicate long-term need for metabolic medication.8. Trauma amplifies metabolic risk.Childhood trauma disrupts IGF-1, sleep, stress hormones, insulin, leptin, and ghrelin.9. Medications can cause weight gain—GLP-1s can help counteract it.Steroids, mood meds, hormonal agents, and more can be metabolically unfriendly.10. “Newer” isn't always better.Some people respond poorly to the GIP component in Mounjaro/Zepbound. Individual physiology rules.Dr. Cooper's Actionable TipsRequest deeper evaluation: DEXA, visceral fat, fasting insulin/glucose, leptin, reproductive hormones.Stop restrictive dieting permanently—mechanical eating protects metabolic stability.Work with a fueling-focused dietitian (often ED-trained).Review your medication list for drugs known to cause weight gain.Don't switch GLP-1s or chase higher doses if your current regimen works.Notable Quote“Obesity isn't a willpower problem. It's a metabolic disease, and when the underlying system is supported, the body finally has permission to change.” — Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

Send us a message with this link, we would love to hear from you. Standard message rates may apply.We share a quick life update, welcome our first guest Mike Rozanski, and clear up the Michelin Guide origin story before shifting to a focused guide on starting GLP-1 medications. Practical strategies cover injections, nausea, constipation, muscle protection, and adjusting other meds safely.• board certification in obesity medicine and motivation to destigmatise care• guest segment on Michelin guide history and Philly's recent stars• what GLP-1 meds are and how auto-injectors work• portion sizing to prevent nausea and early side effects• fiber with fluids to prevent constipation• protein targets and simple strength training to protect muscle• when to adjust blood pressure and diabetes medications• key takeaways and encouragement to start small and follow upIf you found this helpful, a review really does go a long way for a like on whatever app you're listening to us onSupport the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

If you're over 60 and using GLP-1 medications like Wegovy or Zepbound, this episode could save your independence. In this episode, I reveal the hidden danger of rapid weight loss without muscle protection—and the simple strategies that keep you strong, steady, and mobile as the pounds come off. GLP-1 medications are transforming weight loss for older adults managing diabetes, high blood pressure, and joint pain. But there's a critical piece most people miss: sarcopenia. This age-related muscle loss accelerates during weight loss, putting you at risk for falls, fractures, and losing the strength you need for daily activities. Tune in to learn how to lose weight safely while protecting the muscle that keeps you independent—and why strength training, protein intake, and staying active aren't optional on this journey.   Episode Highlights: Why GLP-1 medications like Wegovy and Zepbound are game-changers for adults 60+ The connection between muscle loss, falls, fractures, and loss of independence How sarcopenia affects metabolism, blood sugar control, and bone health Protein requirements for older adults (25-30 grams per meal) Simple strength training routines you can do at home—no gym required Red flags that muscle loss is happening too fast Real patient story: turning weakness into strength on a GLP-1 journey   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In one of our most eye-opening conversations yet, Bo Brabo and Luke Carignan sit down with clinical pharmacist Langley Kyle to unpack the truth behind GLP-1 medications—Wegovy, Ozempic, Zepbound, tirzepatide, and their compounded counterparts. Whether you're an HR leader, benefits strategist, or simply trying to understand why GLP-1s dominate workplace conversations, this episode breaks it all down with clarity, expertise, and a surprising amount of laughter.From skyrocketing utilization to social-media-driven demand, Langley reveals what she's seeing across employer plans nationwide…and what's coming next.

Winner of the CTP Cup for IBIT Announcing the participants for the CTP Cup 2025 Calling a Code Red! Sam Altman’s declaration PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Interactive Brokers  Warm-Up - Winner of the CTP for IBIT - Announcing the participants for the CTP Cup 2025 - Calling a Code Red! Sam Altman's panic - Here come the Tariff lawsuits - - Smart Toilets are a thing (And learning the Bristol Scale) Markets - Horses can smell the barn.... Seasonal Trends - PR Teams - full throttle - (This is their Social Media) - Tax planning over the next couple of weeks may see some selling into year end Impressive Results - India's economy grew at a faster-than-expected pace of 8.2% in the quarter ended September against a forecast of 7.3% in a Reuters poll and 7.8% expansion in the previous quarter, data released last Friday showed. - The Indian government has cut consumer taxes on hundreds of items and implemented long-delayed labour reforms in the last three months as it tries to keep the domestic economy strong in the face of global uncertainties. - Strongest in 6 quarters - Economists said stockpiling for the festive season as well as expedited exports ahead of the 50% tariff deadline on August 27 might have contributed to the quarterly growth figures. - Manufacturing output rose 9.1% in the quarter ending in September from a year earlier against growth of 7.7% a quarter ago, while construction expanded 7.2% year-on-year from 7.6% a quarter ago. NVDA Spreading Out - Nvidia on Monday announced it has purchased $2 billion of Synopsys common stock as part of a strategic partnership to accelerate computing and artificial intelligence engineering solutions. - As part of the multiyear partnership, Nvidia will help Synopsys accelerate its portfolio of compute-intensive applications, advance agentic AI engineering, expand cloud access and develop joint go-to-market initiatives, according to a release. - Nvidia said it purchased Synopsys' stock at $414.79 per share (Now at $445) Amazon Ultra Fast Service - The parent company of Instacart fell nearly 4% after Amazon said it's testing “ultra-fast” delivery of groceries in Seattle and Philadelphia. - These deliveries take about 30 minutes or less, said Amazon. - Doordash and other delivery companies stocks also fell. Microstrategy - Strategy - Stock has been under pressure - Who knows what the company actully does anymore - Leverage Bitcoin play - issuing massive debt and convertibles to but Bitcoin - Stock down 39% this year and 52% 1 -year (Up 400% in the last 5 years) -Bitcoin dropped below $87k this week before staging a recovery bounce. Devil's Metal - Silver has outpaced gold in 2025, with a growth of about 71%, compared to gold's 54%. - Silver mine production has been decreasing for the past ten years, especially in Central and South America, due to mine closures, resource depletion and infrastructure challenges. - While industrial demand for silver is expected to decline slightly in 2025, the metal is increasingly used in electric vehicles, for AI components and in photovoltaics. - Some people are saying that people were having to transport silver by plane rather than on cargo ships to meet delivery demand INTERACTIVE BROKERS Check this out and find out more at: http://www.interactivebrokers.com/ Some Trump Updates: - Reiterates his view that Chair Powell should reduce rates. - Says he's negotiating with Democrats on healthcare. - Plans to give refunds out of collected tariffs. Crying Game - SoftBank Group founder Masayoshi Son on Monday downplayed the decision to offload the conglomerate's entire Nvidia stake, saying he “was crying” over parting with the shares. - Speaking at a forum in Tokyo Monday, Son addressed SoftBank's November disclosure that the firm had sold its holding in the American chip darling for $5.83 billion. - According to Son, SoftBank wouldn't have made the move if it didn't need to bankroll its next artificial intelligence investments, including a big bet on OpenAI and data center projects. Are Stocks Overvalued? CAPE RATIO Consumers... Consumer Confidence CODE RED -  Chief executive Sam Altman reportedly declared a “code red” on Monday, urging staff to improve its flagship product ChatGPT, an indicator that the startup's once-unassailable lead is eroding as competitors like Google and Anthropic close in. - In the memo, reported by the Wall Street Journal and The Information, Altman said the company will be delaying initiatives like ads, shopping and health agents, and a personal assistant, Pulse, to focus on improving ChatGPT. This includes core features like greater speed and reliability, better personalization, and the ability to answer more questions, he said. - Herein lies the problem with this entire tech market - what if ChatGPT fades to the sideline with $1.5Trillion promised over the next 5-7 years? - Remember, Google declared a Code Red after the arrival of ChatGPT. AI Takeover - Massachusetts Institute of Technology on Wednesday released a study that found that artificial intelligence can already replace 11.7% of the U.S. labor market, or as much as $1.2 trillion in wages across finance, health care and professional services. - The study was conducted using a labor simulation tool called the Iceberg Index, which was created by MIT and Oak Ridge National Laboratory. - The index simulates how 151 million U.S. workers interact across the country and how they are affected by AI and corresponding policy. Costco Sues - Costco filed a lawsuit asking for a full refund of tariffs the warehouse club giant has paid since President Donald Trump imposed “reciprocal” and “fentanyl” tariffs earlier this year. - Costco sued the Trump administration to get a full refund of new tariffs it paid so far this year, and to block those import duties from continuing to be collected from the retail warehouse club giant as a Supreme Court case plays out. - Costco is worried that it would lose the money even if the Tariffs were deemed illegal. Fat Cutting -  Eli Lilly said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect. - Starting Dec. 1, cash-paying patients with a valid prescription can pay $299 to $449 per month for Zepbound vials on LillyDirect, depending on the dose, down from a previous range of $349 to $499 per month. - The announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access and afford. Smart Toilets - This year industry giants Toto Ltd. and Kohler Co. introduced smart toilets capable of analyzing what is in the bowl - Launched in August, the latest model in the Neorest line starts at roughly $3,200. - It uses an LED light and a sensor to read the shape, color, hardness and volume of stool as it drops, and sends data to a smartphone app in less than a minute. - Each toilet can support as many as six users — enough for most households — while some companies have bought multiple units for their employees. Toto aims to sell 7,300 units annually by 2028. - For now the stool-scanning Neorest is available only in Japan. - The app analyzes bowel movements against the Bristol scale, which is commonly used to diagnose constipation, inflammation or diarrhea, and offers simple recommendations such as eating more fiber and drinking more water, or even menu suggestions, like vegetable soup. Bristol Scale Feel Good - Entrepreneur Michael Dell and his wife, Susan, will deposit $250 in the individual investment accounts of 25 million American children in a $6.25 billion philanthropic pledge as part of the Trump administration's Invest America initiative. - $250 each child born after between 2015 and 2025 - The money will go to the accounts of children who live in ZIP codes where the median family's income is $150,000 or less, according to a spokesperson for the Dells. Love the Show? Then how about a Donation? Announcing the Winner for iShares Bitcoin Trust ETF (IBIT) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Here is the list of players: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Popular GLP-1 medications like Ozempic, Wegovy, and Zepbound aren’t just transforming weight loss. They’re also changing our intimate lives in surprising ways. In today’s show, we’re diving into results from a new national study finding that a majority of people taking one of these medications reported a change in their sex and dating lives, for better or for worse. My guest is Dr. Amanda Gesselman a research scientist and head of the VIBES research team at the Kinsey Institute at Indiana University. Digital intimacy is a major focus of her research, including how people use tools like camsites, AI companions, dating apps, and social media to navigate connection and desire. Some of the specific topics we explore in this episode include: What specific changes are people noticing in their dating lives as a result of taking one of these drugs? Why does weight loss seem to be benefiting men more than women when it comes to dating? How do GLP-1 medications affect sexual health and function? And is it different for men and women? Are people taking GLP-1 medications worried about social judgement? To learn more, you can read a brief report about the study here. Got a sex question? Send me a podcast voicemail to have it answered on a future episode at speakpipe.com/sexandpsychology. *** Thank you to our sponsors!  Firmtech’s Tech Ring will help you to track your sexual health–and keep it up. Visit myfirmtech.com/justinlehmiller and use code JUSTIN15 for 15% off your purchase.  The Kinsey Institute is where the world turns to understand sex and relationships. You can help continue its expert-led research by donating to the Kinsey Institute Research Fund. Learn more and make a donation here: https://give.myiu.org/centers-institutes/I380010749.html  *** Want to learn more about Sex and Psychology? Click here for previous articles or follow the blog on Facebook, Twitter, or Bluesky to receive updates. You can also follow Dr. Lehmiller on YouTube and Instagram. Listen and stream all episodes on Apple, Spotify, or Amazon. Subscribe to automatically receive new episodes and please rate and review the podcast! Credits: Precision Podcasting (Podcast editing) and Shutterstock/Florian (Music). Image created with Canva; photos used with permission of guest.

The cozy, magical season is here! Leggings, sweaters, cookies, hibernation mode. But this can also become the season where we disconnect from our bodies without even realizing it.In this episode, I'm sharing a truth we don't talk about enough:✨ The longer you hide in leggings and oversized sweatshirts, the longer you stay in denial about where you really are physically and emotionally. ✨ Getting dressed, putting on makeup, and wearing a real outfit isn't about vanity… it's about awareness, identity, and showing up for yourself. ✨ And what I don't want is for you to “wake up” in spring only to realize nothing fits and you don't recognize yourself.Let's talk about how you can stay connected, confident, and present with yourself even during cozy season so you don't lose yourself in the process.

Topics We Cover: 00:00 – New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 – A new oral triple agonist shows record-setting absorption rates 07:00 – Fractal Health's Revita procedure: weight maintenance after stopping GLP-1s 12:00 – Zepbound vial prices drop (full breakdown by dose) 16:00 – Dave's personal experience switching off Mounjaro and intense hunger return 22:00 – Novo Nordisk's EVOKE/EVOKE+ Alzheimer's trial: what the data really means 29:00 – Why GLP-1 neurological research is just getting started 33:00 – Updates on access, partners, and major news coming soon for Medicare patients If you're on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor. Bullet Point Summary of the Podcast Episode New Obesity Measurement Data (Harvard/Mass General Study) Harvard and Mass General propose adding waist circumference to BMI to better diagnose obesity. Traditional BMI misses key factors like muscle mass and body composition. Using the updated measure, Americans classified as obese jumps from ~43% to almost 69%. This means 7 out of 10 U.S. adults would now qualify as having the disease of obesity. Dave notes this validates many people who “feel” metabolically unwell despite a “normal” BMI. Reinforces his claim that “most people should be talking to their doctors about GLP-1s.” New Oral Triple Agonist (Ascletis – ASC41/ASC? Molecule) From Ascletis (A-S-C-L-E-T-I-S), developing an oral triple agonist targeting: GLP-1 GIP Glucagon Similar in mechanism to retatrutide, expected around 2027. Preclinical (animal) data show stunning results: Oral bioavailability of 4.2% 9× higher than tirzepatide 30× higher than oral semaglutide 6× higher than oral retatrutide 57× greater drug exposure than oral retatrutide Half-life ~56 hours Stronger receptor activation than retatrutide in vitro Suggests potential for the first powerful oral triple agonist—worth watching. ️ 3. Discussion of the Gray Market / TikTok Experience Dave briefly recounts losing his TikTok account and landing in an algorithm filled with teenagers promoting gray-market “retatrutide.” Expresses concern over unregulated peptide sales, especially to minors. Fractal Health's New Data – Weight Maintenance After Stopping GLP-1s New results from the Reveal One study (Fractal Health). Participants: lost 24% of body weight on GLP-1s → stopped injections → got one Revita procedure. At 6 months post-GLP-1 discontinuation: Weight changed only 1.5% (vs. ~10% regain in typical off-drug trials) HbA1c barely shifted Safety profile clean Suggests possible long-term weight maintenance without injections through gut mucosal re-lining. Dave describes his own recent attempt to switch drugs and significant hunger return. Food Noise & Biologic Hunger Dave discusses how stopping Mounjaro caused terrifying, primal hunger. Describes the distinction between: Food noise (brain-based thoughts) Hunger signals (biological/animalistic) Reinforces why many patients cannot maintain weight loss without support. Zepbound (Tirzepatide) Cash-Pay Price Reductions Eli Lilly drops cash-pay vial pricing: 2.5 mg: $349 → $299 5 mg: $499 → $399 7.5–15 mg: $499 → $449 Community feedback (informal poll): Most say still too high to leave compounded versions. Many would switch to branded if price hit $200–$300. Dave notes the Most Favored Nations agreement will push GLP-1 prices toward $250/month within 24 months. Alzheimer's Study (Novo Nordisk – EVOKE & EVOKE+) Oral semaglutide (Rybelsus, 14 mg) did not slow Alzheimer's clinical progression. Biomarkers improved but daily function and cognitive decline did not improve vs placebo. Important context: Oral Rybelsus is a weak form of semaglutide; stronger versions (like Wegovy 2.4 mg or upcoming high-dose oral Wegovy) not tested. Weight loss is not desirable in Alzheimer's patients, influencing drug selection. Dave emphasizes: This was a nearly $700M trial and an act of scientific courage. This is NOT the end of GLP-1 Alzheimer's research. Future molecules may target neurological pathways without suppressing appetite. Mentions Lilly's brenipatide, a GIP receptor agonist being developed for: Addiction Opioid dependency Possibly asthma ️ 8. Access, Cost, and Patient Empowerment Highlights Shed as a partner offering telehealth GLP-1 access. Notes many patients hide GLP-1 use from their primary care doctors. Reinforces OTP's mission: better, more honest conversations with clinicians. Shapa (Numberless Scale) & Dave's Personal Update Dave explains how the Shapa numberless scale helped him stay engaged during weight fluctuations. Finds stepping on “zones” (green/gray/blue) less emotionally damaging than numbers. Closing Notes Promises upcoming Eli Lilly savings card update. Encourages subscribing, liking, and enabling notifications for algorithm visibility. Thanks OTP community for amplifying patient-centric obesity medicine news. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this Monday Headline Brief of The Wright Report, Bryan covers the nation's grief and anger after the Washington terror attack, the deepening crisis within America's immigration system, and President Trump's most sweeping border actions yet. He also examines the political backlash, the debate over assimilation, and the global pressures shaping events from Europe to Venezuela. America Mourns and Demands Answers: Staff Sgt. Andrew Wolfe remains in critical condition while Specialist Sarah Beckstrom is laid to rest after last week's terror attack in Washington. DHS confirmed the attacker, Rahmanullah Lakanwal, was a former CIA-backed Afghan Zero Unit fighter who was radicalized after arrival in the United States. Investigators say he drifted between Washington State, Arizona, and the East Coast with little oversight, revealing systemic vetting failures across multiple administrations.   Vetting Breakdown Exposed: Inspector General reports show that over two hundred thousand Afghans brought into the country during the 2021 evacuation were admitted with almost no reliable databases, poor ID verification, and limited interagency cooperation. None received continual vetting after entry. Bryan explains why "strict vetting" is a political myth and why U.S. systems remain unable to verify criminal history, ideology, or cultural fit for many migrants.   Trump Orders the Most Sweeping Immigration Freeze in Decades: The President has paused all asylum applications, halted Afghan visa processing, and instructed his team to permanently pause migration from Third World nations to reset the system. Green card and citizenship requests from nineteen countries are suspended. Trump is also considering the denaturalization of foreign-born citizens who fail loyalty or cultural compatibility standards. Legal scholars note that Section 212(f) of the Immigration and Nationality Act grants the President broad authority to take such steps.   Political Firestorm and Cultural Divide: Republicans and most Independents support a historic crackdown, while Democrats accuse Trump of racism and xenophobia. Some leaders, including Representative Jasmin Crockett and Representative Debbie Wasserman Schultz, blamed the National Guard deployments for the attack. Bryan argues that many progressive lawmakers reject assimilation because they reject the idea of American culture itself, pointing to recent examples in education, media, and politics.   College Degrees Lose Appeal: New polling shows only 33 percent of Americans believe a four-year degree is worth the cost. Interest in vocational training and maritime careers is rising as tuition increases outpace wages. Maritime academies report that graduates earn more than $200,000 a year after six months of work.   The Autopen Controversy: President Trump announced he is canceling all executive actions signed by Joe Biden through the autopen, citing concerns that Biden did not authorize their use. The Justice Department may soon bring cases that will force the Supreme Court to clarify the legality of autopen approvals.   Debate Over Unlawful Orders Heats Up: Reports claim Secretary of War Pete Hegseth ordered a second strike on a cartel boat. Hegseth denies it. Senator Mark Kelly suggested troops should rely on intuition when evaluating orders, which critics warn could lead to chaos and politicized discipline. The issue may shape U.S. operations in the Caribbean.   Global Flashpoints: Venezuela and Europe: Trump rejected demands from Venezuela's Nicolás Maduro for guaranteed amnesty and military control as part of an exit deal. Maduro may attempt a guerrilla resistance if forced out. In Europe, Islamist protests are disrupting Christmas markets in Belgium and Germany, where security costs have surged. France's populist movement is surging in polls as crime tied to migrants fuels public frustration. Portugal's populist party Chega is also now tied for first place in national polling.   Medical News: A major UK study finds that weight loss drugs like Mounjaro and Zepbound must be taken long-term to maintain results, with many patients regaining most of the weight after stopping treatment.   "And you shall know the truth, and the truth shall make you free." - John 8:32     Keywords: Washington DC terror attack Afghan Zero Unit, Rahmanullah Lakanwal vetting failure, Trump asylum freeze Section 212f, de-naturalization debate immigration reform, Jasmin Crockett Guard criticism, Debbie Wasserman Schultz Trump blame, college degree value drop vocational training, autopen Biden executive actions, Hegseth double tap allegation, Venezuela Maduro exit talks, Belgium Germany Christmas market threats, France National Rally Bardella, Portugal Chega Ventura, GLP-1 weight loss drug study UK

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Should I take a GLP-1? Real Patient Scenarios and Expert GuidanceTrying to figure out if a GLP-1 medication is right for you can feel overwhelming. With options like Wegovy, Zepbound, Ozempic, and Mounjaro, it's not just about weight—these medications can also support heart health, liver function, sleep, and blood sugar. Understanding who truly benefits takes the guidance of an expert.Joining me today is Danielle Marston, or Dani, a board-certified nurse practitioner specializing in obesity medicine, weight management, and nutrition counseling. Dani holds a certificate of advanced education in obesity medicine through the Obesity Medicine Association and provides comprehensive care at our clinic, Colorado Wake Care at Green Mountain Partners for Health. She's here to explain how GLP-1s work, their benefits, and who they can help the most.Through real patient scenarios and practical advice, Dani shows how obesity care can be personalized, evidence-based, and approachable.Whether you're curious about starting a GLP-1, considering other treatment options, or just trying to understand what's available, this episode gives you a clear roadmap to make informed decisions and find a plan that actually fits your life.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

Dr. Emily Cooper, Mark Wright, and Andrea Taylor talk with Maria from Buffalo, a longtime listener who shares her lifelong journey with obesity, psoriatic arthritis, and binge eating—and how finally understanding the science of metabolism gave her hope. Maria describes early childhood weight gain, joint damage, and years of restrictive dieting and food shame, then explains how GLP‑1 therapy (Zepbound) plus mechanical eating helped her lose about 50 pounds while eating more food, more often, and with more joy. Dr. Cooper breaks down the underlying biology—leptin, weight set point, the melanocortin pathway, and the impact of pain, sleep, and chronic inflammation on hunger hormones—and reframes obesity as a symptom of deeper metabolic problems, not a character flaw. This episode doubles as a practical, emotionally honest guide for patients trying to navigate a traditional health‑care system without a dedicated metabolic specialist.Key Questions AnsweredHow can rapid childhood weight gain, autoimmune disease, and early joint damage signal serious metabolic dysfunction rather than “too much food” or “not enough exercise”?What is leptin, what does “too low for your size” mean, and how does that affect hunger, weight set point, and weight loss?What is monogenic obesity testing, who might qualify for free genetic screening, and how can results inform (but not necessarily change) treatment?How do GLP‑1 medications like Zepbound work with mechanical eating so someone can lose weight while eating more regularly and with more variety?Which labs (fasting glucose, insulin, leptin, etc.) help uncover hidden metabolic issues, and when is a mixed‑meal test more useful than a simple fasting snapshot?When should brain‑active medications (such as bupropion/naltrexone combinations) be considered, and what trade‑offs and side effects matter?How can patients respectfully push for tests, challenge old “eat less, move more” advice, and set boundaries around weigh‑ins and stigmatizing language?Key TakeawaysIt's not your fault: Rapid childhood weight gain and early‑onset obesity often reflect serious metabolic biology, including rare gene variants, growth phases, and hormone signaling—not gluttony or laziness.Obesity is a symptom: Excess weight is better understood as a side effect of underlying metabolic fires (leptin issues, insulin resistance, brain signaling problems) that need proper diagnosis and treatment.Leptin really matters: Low leptin for your size can act as a biological brake on weight loss, and chronic dieting, under‑fueling, over‑exercise, and some high‑dose supplements can suppress it further.GLP‑1s plus mechanical eating: Medications like Zepbound can quiet food noise and support weight loss, but scheduled, balanced eating is essential to avoid under‑fueling, protect muscle, and support hormones.Pain and sleep are metabolic: Chronic pain and poor sleep increase hunger hormones like ghrelin and disrupt repair processes, worsening metabolic dysfunction unless directly addressed.Script your visits: Bring a printed list of diagnoses, medications, and questions; use patient portals to request specific tests; and practice simple boundary phrases around weighing and diet talk.Notable Quote“This isn't all just caused by diets and things like that. There was an original metabolic problem. It was amplified because of the food restriction and the psychology around it, but you are a product of cumulative insults to your system—not a moral failure.” — Dr. Emily CooperLinks & ResourcesPodcast Home: https://fatsciencepodcast.com/Cooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/Resources and education from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Show Question: questions@fatsciencepodcast.comDr. Cooper direct show email: dr.c@fatsciencepodcast.comFat Science is informational only and does not constitute medical advice.

Send us a message with this link, we would love to hear from you. Standard message rates may apply.We unpack new GLP-1 pricing, coverage hurdles, and whether cash-pay programs make these meds more reachable for diabetes, obesity, and sleep apnea care. Along the way we share candid pros and cons of injections, tease future oral options, and weigh real tradeoffs.• current cash-pay pricing from major manufacturers• differences between Wegovy, Ozempic, and Zepbound• tighter insurance coverage and prior authorization burden• fears about injections and route-of-administration bias• potential oral GLP-1 timelines and cost impact• framing obesity as a chronic, treatable disease• practical tips to explore HSA or FSA options• how to decide if the monthly cost is worth itSupport the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

If you've been waiting for a GLP-1 weight loss medication that doesn't require injections, special timing, or refrigeration—this episode is for you. Learn about the groundbreaking oral pill that could hit the market as early as 2026. For years, effective obesity medications have meant needles. But Orforglipron could change everything. In this episode, I break down the science, clinical trial results, and approval timeline for this first-of-its-kind once-daily pill that delivers GLP-1 benefits without the injection barriers. Whether you're needle-averse, struggle with injection site reactions, or simply want more convenient options, this new medication could expand access to life-changing obesity treatment.   Episode Highlights: What makes Orforglipron different from Wegovy, Zepbound, and oral semaglutide Clinical trial results: 12.4% average weight loss over 72 weeks Why this oral pill doesn't require fasting or special timing like other oral GLP-1s The FDA accelerated review process and potential 2026 approval timeline Who benefits most: patients with needle phobia, injection site reactions, or seeking maintenance therapy What to expect regarding insurance coverage and access once approved   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Before we all slip into our cozy clothes and head toward the candied yams, I wanted to drop in with a quick Thanksgiving episode and a little love note from my heart to yours.Today, I'm sharing what I'm truly grateful for this season: you. Thank you for listening, for hanging with me through the messy seasons, the comebacks, the pauses, the growth, and all the moments in between. This community means more to me than I can ever put into words.I'm also talking about the real-life chaos of the holidays, the emotional weight many of us carry into this week, and some gentle reminders about food, body image, and giving yourself permission to just be you. You don't need to earn your Thanksgiving meal. You don't need to restrict. You don't need to go overboard. You're allowed to enjoy your plate, be present with your people, and let go of the guilt that diet culture tries to hand you.Take what you need, leave what you don't, and know that you're not alone.Wishing you a happy Thanksgiving filled with yummy food, core memories, and zero shame. I'm so grateful for you. 

New weight loss drugs may portend end of “Fat Acceptance” movement; Celebs and Southerners embrace GLP-1s; Trump clears path for more access to diet drugs; Mid- and late-life exercise slash dementia risk; “Ethicists” urge more tick-borne meat allergy to save planet—as alpha-gal syndrome claims first fatality; What's wrong with the melatonin study that claims it leads to heart failure? How to detox 9-11 first-responders? Can weekend warriors obtain same benefits as regular exercisers? 

In this conversation, Gianna discusses the role of GLP-1 medications in weight management, emphasizing that they are tools to support individuals in their health journeys rather than shortcuts. She highlights the importance of building habits and how GLP-1s can reduce resistance in the body, making it easier to achieve health goals.TakeawaysGLP-1s are tools that enhance the effectiveness of your efforts.They help build habits without constant struggle.The use of GLP-1s is not a shortcut but a strategic change.They support the body's processes to function more easily.Feeling your best is achievable with the right support.Weight management requires personal effort alongside medication.GLP-1s can reduce friction in health journeys.Building habits is crucial for long-term success.The relief of effective strategies can be rewarding.Support from GLP-1s can lead to better health outcomes.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor field your most urgent metabolic health questions—exploring care advocacy, novel drug use, lab results, and how to filter fact from fiction in the TikTok age. Dr. Cooper offers clinical clarity, real-world perspective, and actionable hope—with an emphasis on what truly matters for your long-term health and energy.Hear from listeners experiencing real breakthroughs (and challenges) with GLP-1s, get tips for navigating confusing cholesterol results, and learn why self-advocacy and good science matter more than credentials or hype. This is not a quick-fix episode; it's real metabolic medicine, mythbusting, and grounded encouragement for your health journey.Key Questions AnsweredWhat labs and scores best assess your true metabolic risk—and how do you make sense of fasting glucose, glucose-insulin ratio (GIR), and FIB-4?How can you find a medical provider who'll actually give you the time and attention metabolic care requires?Why do GLP-1s benefit more than weight loss alone? Listeners report help with sleep apnea, inflammation, and food noise—what does the science say?How should you reintroduce carbs after restriction, and what's the safest way to monitor (beyond A1C)?What's up with rising cholesterol on Zepbound, and when do you worry?Does serotonin syndrome relate to GLP-1s? (Short answer: No—Dr. Cooper explains why.)What are the dangers of “GLP-1 microdosing” as pushed by social media, and what happens when influencers overstep good science?Key TakeawaysCare that cares: The best doctor isn't always the most credentialed—find someone, MD, NP, or PA, who takes your questions seriously and goes deeper than the surface. Labs that matter: Fasting glucose, insulin, GIR, HbA1c, plus advanced lipid testing (CardioIQ, NMR) are critical for uncovering hidden risk—not just chasing numbers. GLP-1s act broadly: Listeners see gains in sleep, inflammation, and appetite regulation. These benefits are real, not just anecdotal, and Dr. Cooper shares the clinical rationale. Smart fueling, even on GLP-1s: If you lack hunger cues, “mechanical eating” prevents under-fueling and cellular stress—especially important for maintaining muscle and metabolism. Rethinking “microdosing”: TikTok trends are not medical advice—microdosing with black-market GLP-1s is unproven, poorly regulated, and potentially unsafe. Rely on trusted, legal medication sources only. Dr. Cooper's Actionable TipsRequest a full panel for metabolic health: ask your provider about fasting insulin, GIR, HbA1c, lipids, and FIB-4—even if you haven't been flagged as “at risk”. For those on GLP-1s: Don't skip meals; create a schedule with protein and fiber to avoid muscle loss and ensure micronutrient intake. Experiencing cholesterol shifts on medication? Ask for a breakdown (HDL, LDL, particle size) and consider advanced panels (CardioIQ, NMR) to better understand your risk. If reintroducing carbs after restriction, pair them with protein or fat and test glucose/insulin at intervals post-meal to personalize your plan. Avoid unregulated “microdosing” and buy only from reputable, FDA-approved outlets—protect your long-term health over quick fixes. Notable Quote“The most important thing is somebody who cares, not necessarily their degrees.”— Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramAdvanced cholesterol testing: CardioIQ at Quest, NMR at LabCorpFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice. 

Broadcast from KSQD, Santa Cruz on 11-20-2025: Dr. Dawn discusses GLP-1 inhibitors like Zepbound and semaglutide showing unexpected benefits for addiction treatment beyond diabetes and weight loss. Patients in rehab report these drugs mute cravings for alcohol, cocaine, and cigarettes. Multiple studies show reduced substance abuse rates in users, with VA and NIH conducting trials examining brain activity and responses to triggers. With 80,000 annual drug overdose deaths and 48 million Americans having substance abuse disorders, these medications may revolutionize addiction treatment by dampening brain reward circuitry, though costs threaten healthcare budgets. A Stanford twin study found those twins assigned a vegan diet had substantially lower cholesterol, insulin, and body weight compared to their omnivore twins after several months, with LDL dropping 15mg, four pounds more weight loss, and 20% lower insulin. Dr. Dawn explains how a fungal disease decimating Central American frog populations caused 500% malaria increases in some areas. The fungus kills frogs by blocking skin electrolytes until hearts stop, eliminating tadpoles that eat mosquito larvae. Ecosystem collapses followed with algae blooms and snake population drops. She provides other examples showing how species losses affect human health, emphasizing the "one health" movement recognizing ecosystem health as fundamental to human wellbeing. An Australian study found people aged 70+ who listen to or play music regularly had 39% lower dementia rates, though causation remains uncertain. Princeton research shows music activates multiple brain regions simultaneously. Learning instruments increases gray matter, and musical memory remains intact in advanced dementia since it's stored separately from other memories. A caller discusses how modern screen-based activities provide less multisensory engagement than past social experiences like dances. Another caller describes Grover's disease causing persistent itchy skin with no known cause. Dr. Dawn recommends an elimination diet removing common allergens for one month, then reintroducing individually to identify food sensitivities triggering immune responses. Dr. Dawn explains xenotransplantation advances with genetically edited pigs beginning full-scale kidney transplant trials. Companies use CRISPR to disable genes causing immune rejection and insert human genes promoting immune tolerance. With only 10% of global kidney patients receiving organs, these could provide unlimited supply. Other innovations include kidneys with thymus tissue to teach immune tolerance and external pig liver systems as transplant bridges. She concludes noting research showing female dogs remember and prefer humans who demonstrate competence at tasks, while male dogs show no preference.

Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration.Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.Guest: Eshe Nelson, a reporter for The New York Times based in London, where she covers economics and business news.Background reading: How Ozempic's maker lost its shine after creating a wonder drug.What Trump's new drug pricing deal means for people with obesity.Photo: Sergei Gapon/Agence France-Presse — Getty ImagesFor more information on today's episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

Mazel morons! Today Ben's feeling skinny (thank you, Zepbound), Josh's dishing gym wisdom, and together we unpack Ozempic science, LA beauty standards, overpriced popcorn, dopamine traps, why you should never pickle on vacation, and why LA makes everyone just a little hotter. We also confess our screen-time addictions, talk dad life, and end with a What Are Ya Nuts that involves Target, 20 grand in cash, and questionable decision-making. Love ya! Leave us a voicemail here!Follow us on Instagram and TikTok! Sponsors:Caraway - Plus, if you visit Carawayhome.com/GOOD10 you can take an additional 10% off your next purchase.goodwipes - Just buy a pack at Target, Walmart, Kroger—or your local store—then head to goodwipes.com/GOODGUYS, text them your receipt and get reimbursed!Skims - Shop SKIMS Mens at SKIMS.comQuo - Quo is offering my listeners 20% off your first 6 months at Quo.com/goodguysOlipop - Get $2 off a 4-pack of OLIPOP- Works on any flavor of 4-pack, including Spongebob, any retailer at drinkolipop.com/GOODGUYSHome Chef - For a limited time, Home Chef is offering my listeners FIFTY PERCENT OFF and free shipping for your first box PLUS free dessert for life! Go to HomeChef.com/GOODGUYSPlease note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb and Merck, say about the future of the industry and how companies are responding to President Trump's drug-pricing plans, including TrumpRx. WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Further Reading: Novo Nordisk Sweetens Offer for Metsera - WSJ Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk The Day Pharma's Weight-Loss Gold Rush Intensified Pfizer Profit Falls Amid Lower Covid-19 Drug Demand Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera Novo Nordisk to Shake Up Board After Obesity-Market Challenges Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings AbbVie Lifts Profit Outlook as Sales Rise Bristol Myers Squibb Profit Soars, Raises Revenue Guidance Merck Profit Rises on Strong Keytruda Demand GSK Lifts Guidance After Specialty Medicines Boost Sales Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains Learn more about your ad choices. Visit megaphone.fm/adchoices

In the last few years, GLP-1 weight-loss drugs like Ozempic and Zepbound have been radically reshaping the people's lives, changing appetites and health.But the drugs also have the power to affect other parts of consumers' lives, including their romantic relationships.Lisa Miller, who writes about health for The New York Times, tells the story of how these drugs upended one couple's marriage.Guest: Lisa Miller, a domestic correspondent for the Well section who writes about personal and cultural approaches to physical and mental health.Background reading: Weight-loss drugs have lesser-known side effects on relationships.Photo: Katherine Wolkoff for The New York TimesFor more information on today's episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.